

RECORDATI: PUBLIC DISCLOSURE COMPLIANCE

Milan, 18 March 2015 – Please be informed that the following documents are available to the public at the Company's registered office and published on the Company's website (www.recordati.it; Section Investors, Shareholders' Meetings), on the "1info" storage mechanism (www.1info.it) and also on the website of Borsa Italiana S.p.A. (www.borsaitaliana.it) with reference to the Ordinary Shareholders' Meeting called for 15th April, 2015, single call:

- Report issued by the Board of Statutory Auditors on the financial statements as at 31 December 2014;
- Reports issued by the Independent Auditors on the financial statements as at 31 December 2014 and on the consolidated financial statements as at 31 December 2014;
- Directors' Report relating to item 2 of the agenda of the Ordinary Shareholders' Meeting ("Remuneration Policy") above mentioned.

Furthermore, please be informed that the 2014 Report on Remuneration approved by the Board of Directors on 4th March 2015 is available to the public by the means indicated above (with reference to the Company's website: Section Corporate Governance, Remuneration).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2014 was € 987.4 million, operating income was € 231.0 million and net income was € 161.2 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832